{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 243,
  "pageCount": 415,
  "prevPage": 242,
  "nextPage": 244,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a Q&A format to validate the primary claim made in the headline.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/243",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-243",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The KOL stated that key Vykat trial investigators and other endocrinologists are “uncomfortable” with the drug’s diabetes risk and the potential of a post-approval safety-signal fiasco – and feared that Soleno is covering up the risks with “propaganda.”",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2aa-e96c5f8c6494",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.86,
        "x": 0.07,
        "y": 0.63
      },
      "kind": "paragraph",
      "text": "Key investigators and others “uncomfortable” about diabetes risk and potential of a serious post-approval safety problem; “downplaying the side effects”",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5ab4db6-ac1d-4f4d-a4f9-d95ab4f09a8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.86,
        "x": 0.07,
        "y": 0.7
      },
      "kind": "quote",
      "text": "Q: “The diabetes data that’s already in some of these papers seems to be downplayed.” A: “Yeah, I just saw somebody today, and the kid already has diabetes... And I was explaining what people and she’s like, oh, I had no idea... And she said, well, could it make it worse? And I said, absolutely. Like I said it’s — I do feel it’s being downplayed. Having sat through now, I don’t now how many informational sessions before and after it was approved— it feels like propaganda. I really feel they’re downplaying the side effects. And again, I just heard from another endo that I know really well. And he sees a lot of people. And he said the same thing. He goes, I feel really uncomfortable. I feel like they’re downplaying the side effects. And I think when we get it in the general population, I’m not entirely sure what’s going to happen. He goes, but I can’t imagine it’s going to be good. And I said, agreed.” — KOL in the PWS field; involved with Soleno’s clinical program",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1257f10c-fd85-4eb4-8871-46455adfe33b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“I just saw somebody today and the kid already has diabetes...we were talking about what she would have to do as far as monitoring and everything [if on Vykat]...and she’s like, oh, I had no idea...she said, well, could it make it worse...and I said, absolutely...it’s being downplayed...having sat through I don’t know how many informational sessions before and after it was approved - it feels like propaganda...I really feel they’re downplaying side effects.” — KOL in the PWS field; involved with Soleno’s clinical program",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2aa-eeb00ad80270",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85482edb-17f6-4d86-bd89-8a3df98443c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "The KOL stated that key Vykat trial investigators and other endocrinologists are “uncomfortable” with the drug’s diabetes risk and the potential of a post-approval safety-signal fiasco – and feared that Soleno is covering up the risks with “propaganda.”",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6892c4c-45ef-4348-a0ad-4228cd9baa73",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "8373d5d3-9cf6-4ddf-a193-5d221d799464",
      "evidence": "The slide explicitly frames the company's actions as 'propaganda' and 'downplaying' risks to expose potential misconduct.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}